Press Releases

AUSTIN, Texas , July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) to Merck, known as MSD

- Lumos Pharma expects to initiate its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency (PGHD) prior to the end of 2020 - Additional non-dilutive funds expected from anticipated monetization of priority review voucher (PRV) - Cash on hand expected to fund current operations through

AUSTIN, Texas , May 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the company will present at the virtual Jefferies 2020 Healthcare Conference on Tuesday, June 2, 2020 , at

AUSTIN, Texas , May 26, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its first quarter 2020 financial results after market close on Thursday, May 28, 2020 .

AUSTIN, Texas , April 24, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Aaron Schuchart will be joining the company as Chief Business Officer starting on May 6, 2020 . In this role, Mr.

AUSTIN, Texas , April 02, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the promotion of John C. McKew , PhD to the position of Chief Operating Officer, effective April 1, 2020 , in addition

AUSTIN, Texas , March 30, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the appointment of Joseph S. McCracken , DVM, MS to the company's Board of Directors, effective March 23, 2020 .

- Combined company, Lumos Pharma, Inc. , to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash on March 31, 2020 in excess

Special Meeting of Stockholders set for March 17, 2020 for vote on proposed merger of NewLink Genetics and Lumos Pharma AMES, Iowa , Feb. 28, 2020 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the fourth quarter and full year ended December 31,